I have written about the All-Trials Initiative several times. It has many vocal supporters and equally vocal critics – especially in the US. I thought that with the recent EU legislation on full disclosure, the case was pretty much closed, at least in Europe. Nope.
A group of US and UK pension funds and asset managers have lent their support to the All-Trial initiative - and with investments totalling about £2.5 trillion, their support carries rather a lot of clout! Just to hammer the point a little more – that’s £2,500,000,000,000,000!
The investors are writing to the companies, in which they have an interest, asking them to take the following steps:
- Retrospectively register past and ongoing clinical trials, and register all future trials before they begin;
- Publish the methods and full results of all trials, including information on adverse events;
- Post an objective summary of results within one year of completion of the trial, following the guidelines on ClinicalTrials.gov;
- Support efforts to provide independent researchers access to anonymised individual patient data.
Last year, the EU passed legislation that will require all clinical trials conducted in Europe to be registered before they begin and for their results to be reported within a year. However, it will only come into effect in 2016. There is also a question over whether it may be adversely affected by the outcome of a judicial review on the UK's Health Research Authority.
The additional pressure has been welcomed by advocates of openness who maintain that full disclosure would give access to a wealth of useful, and potentially life-saving data.
Read more [here].
|
|
 |
|
|
Share on LinkedIn |
Share via Email |
